Upfront Multiplex Gene Test Helps Prolong Survival in Advanced Non- small Cell Lung Cancer

被引：5

作者：

Kanasaki, Hiroki ^{[1
]}

Ozawa, Yuichi ^{[1
]}

Nakamura, Naoto ^{[1
]}

Nagasaki, Kimihiko ^{[1
]}

Matsuyama, Wataru ^{[1
]}

Akahori, Daisuke ^{[1
]}

Niwa, Mitsuru ^{[1
]}

Ogasawara, Takashi ^{[1
]}

Sato, Jun ^{[1
]}

机构：

[1] Hamamatsu Med Ctr, Dept Resp Med, Hamamatsu, Shizuoka, Japan

来源：

ANTICANCER RESEARCH | 2024年 / 44卷 / 02期

关键词：

Non-small cell lung cancer; multiplex gene test; nextgeneration sequencing; PCR; CRIZOTINIB;

D O I：

10.21873/anticanres.16863

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: Detection of genetic abnormalities is crucial for selecting an appropriate therapy to effectively treat advanced non-small cell lung cancer (NSCLC). Multiplex genetic testing aids the selection of appropriate therapy and tailored treatments; however, its impact on survival remains unexplored. Patients and Methods: Using data from 112 patients with advanced or recurrent NSCLC between February 2020 and April 2023, we investigated the impact of multiplex genetic tests, conducted before the initiation of systemic therapy, on survival. Results: Multiplex genetic test was performed on 72 patients (MPL group). Among the remaining 40 patients (non-MPL group), 18 underwent =1 single-plex genetic test, including tests for EGFR (18), ALK (14), and ROS1 (8). The frequency of EGFR mutations in the MPL and non-MPL groups was similar (28% and 25%, respectively), whereas alterations in KRAS, ALK, MET, HER2, and RET levels (5, 4, 4, 4, and 1, respectively) were exclusively detected in the MPL group. The MPL group exhibited a significantly improved survival rate compared to the non-MPL group (median survival time 20.6 vs. 9.3 months, p= 0.009). Conclusion: Multiplex genetic testing, before the initiation of systemic treatment, could potentially enhance prognosis by uncovering a wide range of non-EGFR gene abnormalities. Multiplex genetic tests could be crucial for the effective application of modern anti-cancer therapeutic strategies.

引用

页码：723 / 730

页数：8

共 12 条

[1] The impact of population-based EGFR testing in non-squamous metastatic non-small cell lung cancer in Alberta, Canada [J].

Brenner, Darren R. ;

O'Sullivan, Dylan E. ;

Jarada, Tamer N. ;

Yusuf, Amman ;

Boyne, Devon J. ;

Mather, Cheryl A. ;

Box, Adrian ;

Morris, Donald G. ;

Cheung, Winson Y. ;

Mirza, Imran .

LUNG CANCER, 2023, 175 :60-67

[2] Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial [J].

Camidge, D. Ross ;

Kim, Hye Ryun ;

Ahn, Myung-Ju ;

Yang, James C. H. ;

Han, Ji-Youn ;

Hochmair, Maximilian J. ;

Lee, Ki Hyeong ;

Delmonte, Angelo ;

Campelo, Maria Rosario Garcia ;

Kim, Dong-Wan ;

Griesinger, Frank ;

Felip, Enriqueta ;

Califano, Raffaele ;

Spira, Alexander I. ;

Gettinger, Scott N. ;

Tiseo, Marcello ;

Lin, Huamao M. ;

Liu, Yuyin ;

Vranceanu, Florin ;

Niu, Huifeng ;

Zhang, Pingkuan ;

Popat, Sanjay .

JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (12) :2091-2108

[3] Genomic Profiling of Advanced Non-Small Cell Lung Cancer in Community Settings: Gaps and Opportunities [J].

Gutierrez, Martin E. ;

Choi, Kelly ;

Lanman, Richard B. ;

Licitra, Edward J. ;

Skrzypczak, Stanley M. ;

Benito, Ruth Pe ;

Wu, Tommy ;

Arunajadai, Srikesh ;

Kaur, Sukhi ;

Harper, Harry ;

Pecora, Andrew L. ;

Schultz, Eric V. ;

Goldberg, Stuart L. .

CLINICAL LUNG CANCER, 2017, 18 (06) :651-659

[4] Real-world treatment and survival of patients with advanced non-small cell lung Cancer: a German retrospective data analysis [J].

Hardtstock, Fraence ;

Myers, David ;

Li, Tracy ;

Cizova, Diana ;

Maywald, Ulf ;

Wilke, Thomas ;

Griesinger, Frank .

BMC CANCER, 2020, 20 (01)

[5] Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs [J].

Kris, Mark G. ;

Johnson, Bruce E. ;

Berry, Lynne D. ;

Kwiatkowski, David J. ;

Iafrate, A. John ;

Wistuba, Ignacio I. ;

Varella-Garcia, Marileila ;

Franklin, Wilbur A. ;

Aronson, Samuel L. ;

Su, Pei-Fang ;

Shyr, Yu ;

Camidge, D. Ross ;

Sequist, Lecia V. ;

Glisson, Bonnie S. ;

Khuri, Fadlo R. ;

Garon, Edward B. ;

Pao, William ;

Rudin, Charles ;

Schiller, Joan ;

Haura, Eric B. ;

Socinski, Mark ;

Shirai, Keisuke ;

Chen, Heidi ;

Giaccone, Giuseppe ;

Ladanyi, Marc ;

Kugler, Kelly ;

Minna, John D. ;

Bunn, Paul A. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 311 (19) :1998-2006

[6]

Levy BP, 2023, J CLIN ONCOL, V41

[7] Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR. [J].

Maemondo, Makoto ;

Inoue, Akira ;

Kobayashi, Kunihiko ;

Sugawara, Shunichi ;

Oizumi, Satoshi ;

Isobe, Hiroshi ;

Gemma, Akihiko ;

Harada, Masao ;

Yoshizawa, Hirohisa ;

Kinoshita, Ichiro ;

Fujita, Yuka ;

Okinaga, Shoji ;

Hirano, Haruto ;

Yoshimori, Kozo ;

Harada, Toshiyuki ;

Ogura, Takashi ;

Ando, Masahiro ;

Miyazawa, Hitoshi ;

Tanaka, Tomoaki ;

Saijo, Yasuo ;

Hagiwara, Koichi ;

Morita, Satoshi ;

Nukiwa, Toshihiro .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (25) :2380-2388

[8] Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial [J].

Mitsudomi, Tetsuya ;

Morita, Satoshi ;

Yatabe, Yasushi ;

Negoro, Shunichi ;

Okamoto, Isamu ;

Tsurutani, Junji ;

Seto, Takashi ;

Satouchi, Miyako ;

Tada, Hirohito ;

Hirashima, Tomonori ;

Asami, Kazuhiro ;

Katakami, Nobuyuki ;

Takada, Minoru ;

Yoshioka, Hiroshige ;

Shibata, Kazuhiko ;

Kudoh, Shinzoh ;

Shimizu, Eiji ;

Saito, Hiroshi ;

Toyooka, Shinichi ;

Nakagawa, Kazuhiko ;

Fukuoka, Masahiro .

LANCET ONCOLOGY, 2010, 11 (02) :121-128

[9] Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer [J].

Nakagawa, Kazuhiko ;

Hida, Toyoaki ;

Nokihara, Hiroshi ;

Morise, Masahiro ;

Azuma, Koichi ;

Kim, Young Hak ;

Seto, Takashi ;

Takiguchi, Yuichi ;

Nishio, Makoto ;

Yoshioka, Hiroshige ;

Kumagai, Toru ;

Hotta, Katsuyuki ;

Watanabe, Satoshi ;

Goto, Koichi ;

Satouchi, Miyako ;

Kozuki, Toshiyuki ;

Koyama, Ryo ;

Mitsudomi, Tetsuya ;

Yamamoto, Nobuyuki ;

Asakawa, Takashi ;

Hayashi, Morihiko ;

Hasegawa, Wakako ;

Tamura, Tomohide .

LUNG CANCER, 2020, 139 :195-199

[10] Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC [J].

Ramalingam, S. S. ;

Vansteenkiste, J. ;

Planchard, D. ;

Cho, B. C. ;

Gray, J. E. ;

Ohe, Y. ;

Zhou, C. ;

Reungwetwattana, T. ;

Cheng, Y. ;

Chewaskulyong, B. ;

Shah, R. ;

Cobo, M. ;

Lee, K. H. ;

Cheema, P. ;

Tiseo, M. ;

John, T. ;

Lin, M-C ;

Imamura, F. ;

Kurata, T. ;

Todd, A. ;

Hodge, R. ;

Saggese, M. ;

Rukazenkov, Y. ;

Soria, J-C ;

Boyer, Michael ;

Lee, Chee ;

Hughes, Brett ;

O'Byrne, Kenneth ;

Briggs, Peter ;

Milward, Michael ;

John, Thomas ;

Demedts, Ingel ;

Vansteenkiste, Johan ;

Bustin, Frederique ;

Barrios, Carlos Henrique ;

Timcheva, Constanta ;

Butts, Charles ;

Goss, Glenwood ;

Juergens, Rosalyn ;

Leighl, Natasha ;

Cheng, Susanna ;

Burkes, Ronald ;

Zhou, Caicun ;

Zhang, Helong ;

Shu, Yongqian ;

Cheng, Ying ;

Zhou, Qing ;

Li, Wei ;

Feng, Guosheng ;

He, Yong .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (01) :41-50

← 1 2 →